GGrantIndex
Sort

21,453 grants matching tuberculosis

Type I IFN-dependent and independent contributions to the outcomes of early innate immune cell interactions during HIV/TB co-infection

$872,144
Christina Leigh Stallings · Washington University · R01 · FY2025 · AI

SigH based attenuated, efficacious Mtb vaccines to protect against lethal TB

$872,044
Deepak Kaushal · Texas Biomedical Research Institute · R01 · FY2020 · AI

A systems analysis of drug tolerance in Mycobacterium tuberculosis

$871,572
Nitin S Baliga · Institute For Systems Biology · R01 · FY2017 · AI

A systems approach to manipulate microbial adaptation to structured environments

$871,106
Nitin S Baliga · Institute For Systems Biology · R01 · FY2023 · AI

Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (HISTO-FACT)

$870,925
Nathan Bahr · University Of Minnesota · R01 · FY2025 · AI

Project 1 Immunometabolic Determinants of Susceptibility

$870,530
Christopher M Sassetti · Univ Of Massachusetts Med Sch Worcester · P01 · FY2024 · AI

Function of granulysin

$870,505
Alan Krensky · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Regulation of RANTES expression in T lymphocytes

$870,505
Alan Krensky · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Integrating genomic and spatial approaches for targeted control of HIV-associated tuberculosis epidemics

$870,052
Theodore H Cohen · Yale University · R01 · FY2020 · AI

The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit.

$869,573
Beatriz Grinsztejn · Fundacao Oswaldo Cruz · UM1 · FY2025 · AI

Role of Coupled Amino Acids in the Mechanisms of Enzyme Catalysis

$869,536
Mary Jo Ondrechen · Northeastern University · · FY2022 · BIO

Development of Aersolized Vaccines

$869,351
Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Lesion-centric optimization of multidrug therapies for tuberculosis

$869,259
Bree Beardsley Aldridge · Tufts University Boston · R01 · FY2020 · AI

Human Genetic Dissection of Exit from Latency in Tuberculosis

$869,244
Jean-Laurent Casanova · Weill Medical Coll Of Cornell Univ · U19 · FY2016 · AI

Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis

$869,240
Shabaana A. Khader · Washington University · R01 · FY2022 · AI

A systems approach to manipulate microbial adaptation to structured environments

$869,107
Nitin S Baliga · Institute For Systems Biology · R01 · FY2022 · AI

Promoting Adherence to TB Regimens in High-Risk Youth

$868,916
San Diego State University · R01 · FY2003 · HL

A systems analysis of drug tolerance in Mycobacterium tuberculosis

$868,716
Nitin S Baliga · Institute For Systems Biology · R01 · FY2024 · AI

ADULT AIDS CLINICAL TRIALS UNIT

$868,304
University Of Pittsburgh At Pittsburgh · U01 · FY2000 · AI

U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT

$868,300
University Of Texas Sw Med Ctr/Dallas · U01 · FY2000 · AI

Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy

$867,492
Jyothi Rengarajan · Emory University · R01 · FY2023 · AI

SigH based attenuated, efficacious Mtb vaccines to protect against lethal TB

$867,304
Deepak Kaushal · Texas Biomedical Research Institute · R01 · FY2022 · AI

VACCINE AND EVALUATION TREATMENT UNITS

$867,107
Robert Belshe · Saint Louis University · N01 · FY2015 · AI

Risk of Neonatal Vaccination for HIV/SIV Exposed Infants

$867,023
Donald L Sodora · Seattle Biomedical Research Institute · R01 · FY2016 · DE

Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome

$866,989
Charles Testa · Curza Inc · R01 · FY2017 · AI